Usana Health Sciences, Inc. (USNA)
USANA Health Sciences: Premium Formulation, Discounted Valuation
USANA Health Sciences' pivot from MLM to omnichannel, highlighted by the Hiya Health acquisition, marks a strategic inflection point for renewed growth and relevance. The company's scientific credibility, strong balance sheet, and global reach position it well, despite recent revenue declines and heavy China exposure. Valuation is attractive at 12× forward earnings and 5× EBITDA, with catalysts including Hiya's growth, margin expansion, and potential buybacks.
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
USANA Health (USNA) Upgraded to Buy: Here's What You Should Know
USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is USANA Health Sciences (USNA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USANA Health Sciences, Inc. (USNA) Q1 2025 Earnings Call Transcript
USANA Health Sciences, Inc. (NYSE:USNA ) Q1 2025 Earnings Conference Call April 23, 2025 11:00 AM ET Company Participants Andrew Masuda - Director, Investor Relations Jim Brown - President and Chief Executive Officer Brent Neidig - Chief Commercial Officer Doug Hekking - Chief Financial Officer Walter Noot - Chief Operating Officer Conference Call Participants Anthony Lebiedzinski - Sidoti & Company Ivan Feinseth - Tigress Financial Partners Operator Greetings. Welcome to the USANA Health Sciences First Quarter Conference Call.
USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.70 per share. This compares to earnings of $0.86 per share a year ago.
USANA Health Sciences, Inc. (USNA) Q4 2024 Earnings Conference Call Transcript
USANA Health Sciences, Inc. (NYSE:USNA ) Q4 2024 Earnings Conference Call February 26, 2025 11:00 AM ET Company Participants Andrew Masuda - IR Jim Brown - President and CEO Brent Neidig - Chief Commercial Officer Doug Hekking - CFO Walter Noot - COO Conference Call Participants Anthony Lebiedzinski - Sidoti Christina Xue - D.A. Davidson Ivan Feinseth - Tigress Financial Partners Doug Lane - Water Tower Research Operator Greetings, and welcome to the USANA Health Sciences' Fourth Quarter Conference Call.
USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.87 per share a year ago.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USNA or STVN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
